MetaVia (NASDAQ:MTVA) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

MetaVia (NASDAQ:MTVA – Get Free Report) posted its earnings results on Thursday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08), FiscalAI reports.

MetaVia Stock Up 2.8%

Shares of MTVA stock traded up $0.04 during mid-day trading on Friday, hitting $1.49. 107,022 shares of the stock were exchanged, compared to its average volume of 549,292. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03. The company has a market cap of $7.69 million, a PE ratio of -0.29 and a beta of 0.95. The firm has a fifty day moving average of $1.72 and a 200 day moving average of $1.75.

Get MetaVia alerts:

Institutional Trading of MetaVia

An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in shares of MetaVia Inc. (NASDAQ:MTVA – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MTVA has been the subject of a number of recent research reports. Wall Street Zen upgraded MetaVia to a “sell” rating in a research note on Saturday, June 20th. HC Wainwright reiterated a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MetaVia presently has an average rating of “Hold” and an average target price of $20.00.

Get Our Latest Analysis on MTVA

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Read More

• Five stocks we like better than MetaVia
• Quantum Earnings Week: Winners and Losers Are Finally Emerging
• Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
• Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
• AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.